High Frequency of PIK3R1 Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations
Cancers · 15.01.2025 · 17 (2) · 269
DOI: 10.3390/cancers17020269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 15.01.2025. Verfasst von Iwona K Rzepecka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Science Centre in Poland, National Science Centre in Poland.
Abstract (Originalsprache)
Background
The phosphoinositide 3-kinase (PI3K) pathway is activated in multiple cancers. However, the significance of PIK3R1 encoding the PI3K regulatory subunit, an inhibitor of the PI3K catalytic subunit encoded by PIK3CA, in ovarian cancer development is largely unknown.
Methods
Here, we investigated PIK3R1 genomic alterations and gene expression by direct sequencing and qPCR methods in 197 ovarian cancers. The results were correlated with clinicopathological and molecular variables and patient outcomes.
Results
In addition to mutations (3.5%) and allelic losses (28.4%), we observed a very high frequency of decreased PIK3R1 mRNA levels in ovarian carcinomas (95.8%). Tumors with PIK3R1 mutations mostly represented low-stage cancers of endometrioid and clear-cell type. Tumors with PIK3R1 deletion and underexpression shared similar phenotypes of high-grade carcinomas (p = 0.003 and p = 0.025, respectively). Allelic loss was also associated with advanced stages (p = 0.003) and high-grade serous histotypes (p = 0.004). The PIK3R1 copy number correlated with mRNA levels (p = 0.009). PIK3R1 mutations coexisted with PTEN mutations (p = 0.041), whereas PIK3R1 deletion and underexpression were linked to PIK3CA amplification (p = 0.038 and p = 0.033, respectively). Low PIK3R1 expression diminished the probability of a complete response (OR 0.07, p = 0.03) in patients treated with platinum-based regimens.
Conclusions
PIK3R1 alterations may contribute to the development of ovarian cancers with different malignant potential and molecular changes. The high frequency of PIK3R1 aberrations suggests their importance in PI3K pathway deregulation, and they may potentially serve as an alternative to PIK3CA markers for therapy with these pathway inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
ORCID-Profile: Iwona K Rzepecka, Jolanta Kupryjanczyk
Förderung
- The National Science Centre in Poland
- National Science Centre in Poland
Zitieren
APA
Rzepecka, I. K., Tysarowski, A., Konopka, B., Dansonka-Mieszkowska, A., & Kupryjanczyk, J. (2025). High Frequency of PIK3R1 Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations. Cancers, 17(2), 269. https://doi.org/10.3390/cancers17020269
Vancouver
Rzepecka IK, Tysarowski A, Konopka B, Dansonka-Mieszkowska A, Kupryjanczyk J. High Frequency of PIK3R1 Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations. Cancers. 2025;17(2):269. doi:10.3390/cancers17020269
BibTeX
@article{Rzepecka2025,
author = {Rzepecka, Iwona K and Tysarowski, Andrzej and Konopka, Bozena and Dansonka-Mieszkowska, Agnieszka and Kupryjanczyk, Jolanta},
title = {High Frequency of PIK3R1 Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations},
journal = {Cancers},
year = {2025},
volume = {17},
number = {2},
pages = {269},
doi = {10.3390/cancers17020269}
}
EUVIMED